OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of the European Academy of Dermatology and Venereology is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children	255
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations	182
European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy	161
Cutaneous findings following COVID‐19 vaccination: review of world literature and own experience	150
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations	106
European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II	104
European guideline (EuroGuiDerm) on atopic eczema – part II: non‐systemic treatments and treatment recommendations for special AE patient populations	103
Photoprotection according to skin phototype and dermatoses: practical recommendations from an expert panel	100
UpdatedS2K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)	97
2021 European guideline on the management of Mycoplasma genitalium infections	91
Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis	79
Common causes of hair loss – clinical manifestations, trichoscopy and therapy	78
Prevalence of most common skin diseases in Europe: a population‐based study	75
European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I	73
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real‐life study	72
The first dose of COVID‐19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?	70
Lichen planus arising after COVID‐19 vaccination	68
Line‐field confocal optical coherence tomography of basal cell carcinoma: a descriptive study	67
3D wide‐field multispectral photoacoustic imaging of human melanomas in vivo: a pilot study	67
Emerging antifungal treatment failure of dermatophytosis in Europe: take care or it may become endemic	66
Psoriasis exacerbation after COVID‐19 vaccination: a report of 14 cases from a single centre	63
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled t	63
A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy	61
Transient cutaneous manifestations after administration of Pfizer‐BioNTech COVID‐19 Vaccine: an Italian single‐centre case series	59
Development of severe pemphigus vulgaris following SARS‐CoV‐2 vaccination with BNT162b2	59

Skin manifestations of the BNT162b2 mRNA COVID‐19 vaccine in healthcare workers. ‘COVID‐arm’: a clinical and histological characterization	56
Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis	55
Varicella‐zoster and herpes simplex virus reactivation post‐COVID‐19 vaccination: a review of 40 cases in an International Dermatology Registry	54
New‐onset cutaneous lichen planus triggered by COVID‐19 vaccination	53
Epidermal thickness in healthy humans: a systematic review and meta‐analysis	53
SARS‐CoV‐2‐induced telogen effluvium: a multicentric study	51
Adult skin acute stress responses to short‐term environmental and internal aggression from exposome factors	49
Cutaneous adverse reactions after m‐RNA COVID‐19 vaccine: early reports from Northeast Italy	48
Stigma in visible skin diseases – a literature review and development of a conceptual model	47
Epidemiological and clinical aspects of Trichophyton mentagrophytes/Trichophyton interdigitale infections in the Zurich area: a retrospective study using genotyping	47
European recommendations for management of immune checkpoint inhibitors‐derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement	46
Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA	46
A systematic review of worldwide data on tinea capitis: analysis of the last 20 years	45
Prompt onset of Rowell's syndrome following the first BNT162b2 SARS‐CoV‐2 vaccination	45
Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB Registry: EB more common than previously assumed?	43
Prevalence, comorbidities and mortality of generalized pustular psoriasis: A literature review	43
Pityriasis rosea‐like eruptions following vaccination with BNT162b2 mRNA COVID‐19 Vaccine	42